BioWorld Asia

Jan. 26, 2005

OctoPlus Raises EUR18.25M For Drug Development, Delivery

OctoPlus BV raised €18.25 million (US$23.6 million) in a second funding round that will enable it to progress its drug development and delivery programs and to widen its product pipeline. (BioWorld International) Read More

CeNeS Gets Positive Phase III Data For M6G, Plans Another

Immune Cells Reprogrammed As Cancer Killers, Study Shows

Stroke Company Paion AG Testing German IPO Waters

Crucell Mulls Funding Moves For Clinical Studies In 2005

UroGene Sells Research Center, Cancer Programs to Pierre Fabre

With More Phase III Data, GW Hoping For IND Filing In U.S.

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 22, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.